ANI Pharmaceuticals, Inc. Cash Flow Statement
ANIP / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
ANI Pharmaceuticals, Inc. generated $185M in operating cash flow and $171M in free cash flow in FY2025. Free cash flow margin was 19.4% of revenue.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $78.3M | -$18.5M | $18.8M | -$47.9M | -$42.6M | -$22.5M | $6.1M | $15.5M | -$1.1M | $3.9M | $301.0K | $28.7M | -$1.5M | -$1.5M | - |
| Depreciation & Amortization | $91.4M | $67.7M | $59.8M | $57.0M | $47.3M | $44.6M | $44.6M | $33.7M | $27.9M | $22.3M | $1.1M | $3.9M | $567.0K | $567.0K | $148.2K |
| Operating Cash Flow | $185.2M | $64.0M | $119.0M | -$31.2M | $3.3M | $15.3M | $45.6M | $67.1M | $39.4M | $27.5M | -$5.5M | $22.0M | -$137.0K | -$137.0K | -$47.9M |
| Capital Expenditures | $13.8M | $16.2M | $8.9M | $8.9M | $2.6M | $6.1M | $6.6M | $5.7M | $10.4M | $4.6M | $191.0K | $1.1M | $292.0K | $292.0K | $719.9K |
| Free Cash Flow | $171.4M | $47.8M | $110.1M | -$40.1M | $765.0K | $9.1M | $39.0M | $61.3M | $29.1M | $22.9M | -$5.7M | $20.9M | -$429.0K | -$429.0K | -$48.6M |
| Share Buybacks | $12.2M | $11.0M | $5.0M | $2.0M | $890.0K | $1.5M | $1.0M | $0 | $0 | $2.5M | $433.0K | $0 | $0 | $0 | - |
| Dividends Paid | $1.2M | $1.6M | $1.6M | $1.6M | $190.0K | $0 | $0 | - | - | - | - | - | - | - | - |
| FCF Margin | 19.4% | 7.8% | 22.6% | -12.7% | 0.4% | 4.4% | 73.7% | 30.4% | 16.4% | 17.8% | -18.9% | 37.4% | -2.1% | -2.1% | -11166.0% |